Alan F Schatzberg, MD
Psychiatry · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Schatzberg’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G27191 · Current
Licensed to practise in California · since 1974 · expires 2026-10-31 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$7,008
Medicare paid this office $7,008 for 14 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 11 | $2,975 | $114 |
Who their Medicare patients are
14 Original Medicare patients in 2024. Average age 74 · Health risk score 1.31. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
The office billed $28,774, Medicare allowed $9,183 and paid $7,008; for 61 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 14 | 61 | 74 | 1.31 | $28,774 | $7,008 |
| 2023 | 15 | 117 | 71 | 0.89 | $42,524 | $8,027 |
| 2022 | 11 | 80 | 75 | 1.66 | $30,190 | $5,050 |
| 2021 | 11 | 39 | 74 | 1.30 | $15,305 | $2,822 |
| 2020 | 15 | 54 | 70 | 1.19 | $24,326 | $3,501 |
| 2018 | 13 | 33 | 73 | 0.91 | $3,596 | $2,556 |
| 2017 | 12 | 25 | 71 | 0.86 | $5,101 | $1,822 |
| 2016 | 12 | 37 | 74 | 1.61 | $6,988 | $2,507 |
| 2015 | 15 | 49 | 73 | 2.00 | $9,655 | $3,353 |
| 2014 | 13 | 61 | 73 | 1.30 | $9,576 | $3,951 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Telehealth originating site facility fee | 11 | $1,235 | $22 |
2022: 1 service
| Telehealth originating site facility fee | 11 | $790 | $20 |
2021: 1 service
| Telehealth originating site facility fee | 11 | $411 | $22 |
2020: 1 service
| Telehealth originating site facility fee | 13 | $489 | $21 |
Drugs they prescribed that Part D paid
$22,232
Pharmacies billed $22,232 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 140) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
140 generic and 0 brand-name prescriptions · $22,232 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lurasidone | 12 | $18,519 | $1,543 |
| Divalproex | 12 | $643 | $54 |
| Mirtazapine | 12 | $602 | $50 |
| Olanzapine | 15 | $582 | $39 |
| Pramipexole Dihydrochloride | 13 | $450 | $35 |
See all 8 drugs
| Lurasidone | 12 | $18,519 | $1,543 |
| Divalproex | 12 | $643 | $54 |
| Mirtazapine | 12 | $602 | $50 |
| Olanzapine | 15 | $582 | $39 |
| Pramipexole Dihydrochloride | 13 | $450 | $35 |
| Bupropion Hcl Sr | 12 | $358 | $30 |
| Venlafaxine Hcl Er | 16 | $225 | $14 |
| Bupropion Xl | 11 | $156 | $14 |
Year by year
| 2024 | 140 | 14 | 0% (0) | 0% | $22,232 |
| 2023 | 141 | 11 | 0% (0) | None | $16,202 |
| 2022 | 132 | None | 0% (0) | 9% | $24,469 |
| 2021 | 121 | None | 0% (0) | 10% | $20,769 |
| 2020 | 163 | None | 0% (0) | 12% | $24,444 |
| 2019 | 142 | 14 | 0% (0) | 11% | $22,432 |
| 2018 | 186 | 16 | 0% (0) | 18% | $36,588 |
| 2017 | 158 | 13 | 0% (0) | 19% | $40,262 |
| 2016 | 144 | 13 | 0% (0) | 12% | $25,299 |
| 2015 | 158 | 11 | 0% (0) | 22% | $30,260 |
| 2014 | 209 | 14 | 0% (0) | 17% | $19,811 |
| 2013 | 153 | 12 | 0% (0) | None | $4,683 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Divalproex | 12 | $1,183 | $99 |
| Mirtazapine | 12 | $824 | $69 |
| Pramipexole Dihydrochloride | 15 | $527 | $35 |
| Bupropion Hcl Sr | 11 | $391 | $36 |
| Risperidone | 12 | $242 | $20 |
| Venlafaxine Hcl Er | 28 | $151 | $5 |
2022: 6 drugs
| Latuda | 12 | $21,130 | $1,761 |
| Mirtazapine | 16 | $820 | $51 |
| Fluoxetine | 16 | $362 | $23 |
| Pramipexole Dihydrochloride | 19 | $295 | $16 |
| Risperidone | 12 | $259 | $22 |
| Venlafaxine Hcl Er | 18 | $88 | $5 |
2021: 6 drugs
| Latuda | 12 | $17,165 | $1,430 |
| Mirtazapine | 20 | $874 | $44 |
| Bupropion Hcl Sr | 11 | $540 | $49 |
| Fluoxetine | 16 | $326 | $20 |
| Venlafaxine Hcl Er | 16 | $282 | $18 |
| Risperidone | 12 | $142 | $12 |
2020: 9 drugs
| Latuda | 13 | $17,625 | $1,356 |
| Mirtazapine | 19 | $831 | $44 |
| Bupropion Xl | 11 | $432 | $39 |
| Fluoxetine | 15 | $328 | $22 |
| Venlafaxine Hcl Er | 23 | $182 | $8 |
| Risperidone | 12 | $89 | $7 |
| Lamotrigine | 11 | $80 | $7 |
| Alprazolam | 12 | $35 | $3 |
| Clonazepam | 11 | $30 | $3 |
2019: 5 drugs
| Mirtazapine | 18 | $1,024 | $57 |
| Venlafaxine Hcl Er | 16 | $763 | $48 |
| Risperidone | 13 | $687 | $53 |
| Fluoxetine | 16 | $619 | $39 |
| Lamotrigine | 14 | $113 | $8 |
2018: 7 drugs
| Effexor Xr | 12 | $14,850 | $1,237 |
| Venlafaxine Hcl Er | 22 | $1,050 | $48 |
| Risperidone | 21 | $700 | $33 |
| Mirtazapine | 16 | $657 | $41 |
| Fluoxetine | 12 | $418 | $35 |
| Bupropion Xl | 18 | $315 | $18 |
| Lamotrigine | 12 | $89 | $7 |
2017: 6 drugs
| Effexor Xr | 12 | $13,100 | $1,092 |
| Fanapt | 11 | $10,748 | $977 |
| Aripiprazole | 12 | $5,134 | $428 |
| Mirtazapine | 24 | $649 | $27 |
| Venlafaxine Hcl Er | 24 | $216 | $9 |
| Bupropion Xl | 12 | $119 | $10 |
2016: 5 drugs
| Effexor Xr | 11 | $10,117 | $920 |
| Aripiprazole | 15 | $6,967 | $464 |
| Mirtazapine | 23 | $459 | $20 |
| Bupropion Hcl Sr | 21 | $375 | $18 |
| Fluoxetine | 11 | $370 | $34 |
2015: 7 drugs
| Effexor Xr | 12 | $9,275 | $773 |
| Exelon | 12 | $5,253 | $438 |
| Buspirone | 11 | $596 | $54 |
| Bupropion Xl | 14 | $520 | $37 |
| Mirtazapine | 36 | $372 | $10 |
| Bupropion Hcl Sr | 21 | $252 | $12 |
| Fluoxetine | 13 | $163 | $13 |
2014: 7 drugs
| Bupropion Xl | 24 | $976 | $41 |
| Venlafaxine Hcl Er | 16 | $589 | $37 |
| Mirtazapine | 35 | $555 | $16 |
| Buspirone | 12 | $529 | $44 |
| Doxepin | 12 | $385 | $32 |
| Bupropion Hcl Sr | 19 | $265 | $14 |
| Fluoxetine | 12 | $171 | $14 |
2013: 8 drugs
| Bupropion Xl | 17 | $798 | $47 |
| Buspirone | 14 | $633 | $45 |
| Venlafaxine Hcl Er | 13 | $494 | $38 |
| Mirtazapine | 31 | $391 | $13 |
| Quetiapine | 12 | $365 | $30 |
| Doxepin | 13 | $350 | $27 |
| Bupropion Hcl Sr | 13 | $339 | $26 |
| Fluoxetine | 12 | $157 | $13 |
Money from drug and device companies
$21,401 in 2025
| 2025 | 1 | 7 | $20,000 | $21,401 |
| 2024 | 2 | 21 | $64,725 | $68,492 |
| 2023 | 2 | 17 | $21,800 | $25,672 |
| 2022 | 4 | 17 | $55,900 | $58,096 |
| 2021 | 4 | 28 | $28,600 | $30,740 |
| 2020 | 2 | 4 | $3,296 | $3,296 |
| 2019 | 4 | 12 | $10,954 | $11,725 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sage Therapeutics | Zurzuvae | $21,401 | 7 payments
|
See all 7 published payments
| Sage Therapeutics | Consulting · 2025-09-25 | None | $10,000 |
| Sage Therapeutics | Consulting · 2025-04-17 | None | $10,000 |
| Sage Therapeutics | Travel · 2025-02-13 | Zurzuvae | $8 |
| Sage Therapeutics | Travel · 2025-02-13 | Zurzuvae | $150 |
| Sage Therapeutics | Travel · 2025-02-13 | Zurzuvae | $960 |
| Sage Therapeutics | Travel · 2025-02-13 | Zurzuvae | $118 |
| Sage Therapeutics | Travel · 2025-02-13 | Zurzuvae | $165 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $68,492
| Sage Therapeutics | Zurzuvae | $62,521 | 10 payments
|
| Janssen Scientific Affairs | None | $5,971 | 11 payments
|
2023: $25,672
| Sage Therapeutics | None | $23,872 | 15 payments
|
| Boehringer Ingelheim International GmbH | None | $1,800 | 2 payments
|
2022: $58,096
| Sage Therapeutics | None | $52,049 | 11 payments
|
| Boehringer Ingelheim International GmbH | None | $3,400 | 3 payments
|
| Tris Pharma | Dyanavel Xr | $2,500 | 1 payment
|
| Grifols S.A. | None | $147 | 2 payments
|
2021: $30,740
| Otsuka Pharmaceutical Development & Commercialization | None | $11,573 | 9 payments
|
| Sage Therapeutics | None | $11,467 | 15 payments
|
| Tris Pharma | None | $5,000 | 2 payments
|
| Boehringer Ingelheim International GmbH | None | $2,700 | 2 payments
|
2020: $3,296
| Tris Pharma | None | $2,000 | 1 payment
|
| Otsuka America Pharmaceutical | None | $1,296 | 3 payments
|
2019: $11,725
| Sunovion Pharmaceuticals | None | $5,904 | 1 payment
|
| Jazz Pharmaceuticals | Sunosi | $3,509 | 8 payments
|
| Janssen Research & Development | Spravato | $1,612 | 2 payments
|
| Pfizer | Celebrex | $700 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Prospective, Longitudinal, Observational Study To Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded To Antidepressant Treatment · 2019 | Their institution | $8,962 |
| Neuronetics, Inc. · A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of Neurostar Transcranial Magnetic Stimulation (Tms) Therapy in Depressed Adolescents · 2019 | This clinician | $4,125 |
| Boehringer Ingelheim International GmbH · Proof of Concept and Drf With Trpc4/5 Inhibitor in Mdd · 2024 | This clinician | $1,800 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1518093129
- Licence
- CA G27191California G27191: Current · expires 2026-10-31
- Trained
- New York University School of Medicine, 1968
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-26
- NPI last updated
- 2024-04-30
- NPI record certified
- 2024-04-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2680 Hanover St, Palo Alto, CA, 94304